Open Access

Identification of positron emission tomography (PET) tracer candidates by prediction of the target-bound fraction in the brain

  • Markus Fridén1, 2,
  • Marie Wennerberg3,
  • Madeleine Antonsson3,
  • Maria Sandberg-Ställ4,
  • Lars Farde5 and
  • Magnus Schou5Email author
EJNMMI Research20144:50

DOI: 10.1186/s13550-014-0050-6

Received: 4 July 2014

Accepted: 7 September 2014

Published: 23 September 2014

Abstract

Background

Development of tracers for imaging with positron emission tomography (PET) is often a time-consuming process associated with considerable attrition. In an effort to simplify this process, we herein propose a mechanistically integrated approach for the selection of tracer candidates based on in vitro measurements of ligand affinity (Kd), non-specific binding in brain tissue (Vu,brain), and target protein expression (Bmax).

Methods

A dataset of 35 functional and 12 non-functional central nervous system (CNS) PET tracers was compiled. Data was identified in literature for Kd and Bmax, whereas a brain slice methodology was used to determine values for Vu,brain. A mathematical prediction model for the target-bound fraction of tracer in the brain (ftb) was derived and evaluated with respect to how well it predicts tracer functionality compared to traditional PET tracer candidate selection criteria.

Results

The methodology correctly classified 31/35 functioning and 12/12 non-functioning tracers. This predictivity was superior to traditional classification criteria or combinations thereof.

Conclusions

The presented CNS PET tracer identification approach is rapid and accurate and is expected to facilitate the development of novel PET tracers for the molecular imaging community.

Keywords

Positron emission tomography Non-specific binding Imaging Receptor occupancy

Background

Positron emission tomography (PET) is a molecular imaging technique that is being increasingly used in medical research and drug development. The non-invasive nature of PET, the low chemical mass of the radiolabeled probe used in the emission measurement (usually only micrograms), and the relatively low radiation burden associated with a PET measurement have positioned PET as one of the key enabling technologies in translational medicine. PET can be applied for a wide range of purposes, but all are crucially dependent on the availability of suitable radiotracers for the emission measurements.

The development of PET tracers for the central nervous system (CNS) is often a time-consuming process associated with considerable attrition. Thus, despite the plethora of novel targets of interest for PET imaging, the availability of useful tracers constitutes a bottleneck in nuclear medicine and drug industry. The high attrition rate in tracer development can be attributed to the many properties that a successful CNS tracer has to satisfy including tracer affinity, non-specific binding, blood-brain barrier transport, metabolic stability, etc. (Figure 1) [1]-[5].
Figure 1

Commonly applied criteria for CNS candidate tracer selection.

Over the years, considerable efforts have been directed to the development of methods for selection of CNS PET tracer candidates. In particular, the prediction of non-specific brain tissue binding has been in focus, for which in silico, in vitro, or bio-mathematical methods have been applied [6]-[9]. Recently, a selection method comprising the composite of weighted physicochemical parameters (CNS PET multiparameter optimization or `MPO'), free fractions in plasma and the brain, as well as membrane permeability has been reported [10].

The aim of the present work was to develop and examine an integrated model for identification of promising CNS tracer candidates. The model includes only estimates of non-specific binding, tracer affinity, and target protein expression in the brain. The outcome parameter is the target-bound fraction of tracer in the brain (ftb). The model was validated on a set of 47 successful or failed tracer developments.

Methods

CNS PET tracer dataset

A CNS PET tracer dataset was generated by compilation of 31 PET tracers that either have been evaluated in house at the PET centre at Karolinska Institutet, Sweden, or are related to targets that have been examined at the PET centre. Complementing this dataset, a subset of 18 tracers with measured unbound fraction in brain homogenate was included from a recently published CNS PET tracer database [10]. Tracers were classified as functional or non-functional based on their utility in vivo for reliable quantification of specific target binding. Two tracer molecules were excluded from the dataset: [11C]GSK215083 due to insufficient selectivity and [11C]RWAY due to radioactive metabolites that potentially confounded PET images. The final dataset comprised 35 validated functioning PET tracers and 12 non-functioning tracers (Table 1).
Table 1

CNS PET tracer dataset a

  

Target

In vitrodata

PET data

 

Bmax

Kd

Vu,brain

ftb

BPND

ftb

 

(nM)b

(nM)

(mL/g brain)

   

[18 F]2-FA-85380

Yes

nAChr a4b2

0.7

0.145

1.7

0.74

1.8

0.64

[11C]AFM

Yes

SERT

38

1.04

46

0.44

1.4

0.58

[18 F]Altanserin

Yes

5HT2a

89

0.32

122

0.70

1.06

0.51

[11C]AZ10419369

Yes

5HT1b

9.8c

0.37

30

0.47

1.3

0.57

[11C]AZD2184

Yes

Amyloid

1,407

4.9

33

0.90

1.1

0.52

[11C]AZD2995

Yes

Amyloid

1,407

6.2

7

0.97

0.6

0.38

[18 F]AZD4694

Yes

Amyloid

1,407

2.3

205

0.75

1.2

0.55

[11C]CP-126998

Yes

AchE

211

0.48

41

0.92

  

[11C]DASB

Yes

SERT

38

3.5

31

0.26

1.6

0.62

[18 F]Fallypridef

Yes

D2

27

0.03

18

0.98

22.2

0.96

[18 F]Fallyprideg

Yes

D2

0.9

0.03

18

0.63

2.11

0.68

[18 F]FE-PE2I

Yes

DAT

212

12

62

0.22

4.1

0.80

[18 F]FEPPA[iv]

Yes

TSPO

58

0.07

15

0.98

4.4

0.81

[11C]FLB457

Yes

D2

0.9

0.02

26

0.63

2.6

0.72

[11C]Flumazenil

Yes

GABA

71

0.7

3.2

0.97

5.8

0.85

[18 F]FP-CIT

Yes

DAT

212

33

36

0.15

1.0

0.50

[11C]GR103545

Yes

KOR

3.75c

0.048

41

0.66

2.18

0.69

[11C]GR205171

Yes

NK1

55

0.016

57

0.98

14.5

0.94

[11C]GSK189254A

Yes

H3

8.4

0.08

8.5

0.93

1.3

0.57

[11C]Harmine

Yes

MAO-A

270

5

25

0.68

1.7

0.63

[11C]MADAM

Yes

SERT

38

0.06

90

0.88

1.4

0.58

[11C]McN5652

Yes

SERT

38

0.2

238

0.44

0.50

0.33

[11C]MDL100907

Yes

5HT2a

89

0.24

17

0.96

1.3

0.57

[11C]MePPEP

Yes

CB1r

47

0.1

296

0.61

5.5

0.85

[18 F]MPPF

Yes

5HT1a

350

3.3

14

0.89

1.6

0.62

[11C]NNC112

Yes

D1

93

0.18

70

0.88

2.85

0.74

[11C]PBR28

Yes

TSPO

58

1.8

11

0.75

3.99

0.80

[11C]PE2I

Yes

DAT

212

4.9

39

0.53

8.0

0.89

[11C]PHNO

Yes

D2/D3

26.5d

0.56

11

0.81

2.5

0.71

[11C]PIB

Yes

Amyloid

1,407

2.5

250

0.69

0.85

0.46

[11C]PK11195

Yes

TSPO

58

4.3

59

0.19

0.18

0.15

[11C]Raclopride

Yes

D2

27

2.5

9.4

0.53

2.6

0.72

[18 F]Spiperone

Yes

D2

27

0.028

147

0.87

  

[11C]SB207145

Yes

5HT4

21

0.037

4.4

0.99

3.4

0.77

[11C]SCH23390

Yes

D1

93

2.1

32

0.58

1.8

0.64

[11C]WAY100635

Yes

5HT1a

350

1.1

14

0.96

7.4

0.88

[11C]Citalopram

No

SERT

38

4.8

60

0.12

0.1

0.09

[11C]Clomipramine

No

SERT

38

0.15

863

0.23

0.1

0.09

[11C]CPEB[iv]

No

ORL-1

13.5e

1.1

143

0.08

0.1

0.09

[11C]Desipramine

No

NET

5

0.63

264

0.03

0.1

0.09

[11C]Diazepam

No

GABA

71

7

20

0.34

0.1

0.09

[11C]MeNER

No

NET

5c

2.5

31

0.06

0.3

0.23

[11C]NE100

No

Sigma

23e

1.2

96

0.17

0.1

0.09

[11C]Nisoxetine

No

NET

5

0.73

58

0.11

0.1

0.09

[18 F]Paroxetine

No

SERT

38

0.065

876

0.40

0.1

0.09

[11C]Remoxipride

No

D2

27

270

6.3

0.02

0.1

0.09

[11C]Sertraline

No

SERT

38

0.15

4,184

0.06

0.1

0.09

[11C]Venlafaxine

No

SERT

38

7.5

10

0.33

0.1

0.09

aAn extended version of this table is provided as supporting information (Additional file 1: Table S1), which includes literature references to Bmax, Kd, and BPND for each tracer, details of Vu,brain determination, calculated molecular descriptors and CNS PET MPO score, and the region of brain tissue interest.

bData refers to human brain tissue unless otherwise specified.

cMonkey.

dDog.

eRat.

fBmax value refers to caudate.

gBmax value refers to thalamus.

For each tracer, target density (Bmax), the affinity (Kd) of the tracer for the target, and the non-displaceable binding potential (BPND) were obtained from the literature. A single value of Kd was entered into the database even if more than one value has been reported in literature. Selection preference was given to (1) reports containing data from human material, (2) reports containing data on both Kd, Bmax, or BPND, or (3) the first encountered report.

The unbound volume of distribution in the brain (Vu,brain) describing the extent of non-specific partitioning was determined for 31 tracers using a previously described high-throughput brain slice method [11]. Compound material was not available for 16 tracers and Vu,brain was instead calculated from reported measurements of unbound fraction in homogenized brain tissue and the tracer pKa using a pH-partition model [12]. Molecular descriptors including ClogP, ACDlogD7.4, polar surface area (PSA), molecular weight (MW), hydrogen bond donor count (HBD), and ACDpKa were calculated and used to generate the CNS PET multiparameter optimization (MPO) score [10]. An extended version of Table 1 with complete literature references is provided as supplementary material and includes the calculated molecular properties (Additional file 1).

Equations and relationships

A mathematical relationship for ftb was derived from a model of the total concentration of tracer in brain tissue (Cbrain, pmol/g brain) comprising non-specific tracer and target-bound tracer. The concentration of non-specific tracer is determined by the product of Vu,brain (mL/g brain) and the unbound tracer concentration in the brain interstitial fluid (Cu,brainISF, nmol/L ISF). The concentration of target-bound tracer is described by a non-linear expression with Cu,brainISF, Kd (nmol/L), and Bmax (nmol/g brain) (Eq. 1).
C brain = C u , brainISF × V u , brain + B max × C u , brainISF C u , brainISF + K d
(1)
The relative proportion of the specific binding term in Cbrain, i.e. the target-bound fraction (ftb), is derived from Eq. 1 (Eq. 2) and simplifies under the conditions of Cu,brainISF < < Kd (Eq. 3).
f tb = 1 1 + V u , brain × K d + C u , brainISF B max
(2)
f tb = 1 1 + V u , brain × K d B max
(3)
It is seen from Eq. 2 that the value of ftb (1) increases with increasing target density, (2) decreases with increasing non-specific binding (Vu,brain), and (3) increases with increasing affinity to the target protein (Kd). As illustrated in Figure 2, ftb is additionally dependent on Cu,brainISF and has a plateau maximum value at infinitesimally low concentrations of tracer.
Figure 2

Concentration dependence of f tb for a hypothetical functioning PET tracer (solid line, Eq.2). Blue and red areas represent the proportions of target-bound tracer and non-specific tracer in brain tissue, respectively. At low concentrations (Cu,brainISF < < Kd), ftb is at a plateau maximum value, which is high for functioning tracers and low for non-functioning tracers. At excessive concentrations (Cu,brainISF > > Kd), the specific binding is saturated and ftb negligible also for a good tracer.

To facilitate comparison of in vitro predictions of ftb and in vivo PET studies, a relationship (Eq. 4) was established with BPND, which is essentially the ratio of Bmax and the Kd × Vu,brain product [13].
f tb = BP ND 1 + BP ND
(4)

While the relationships described above follows the terminology used to describe pharmacokinetics of drug transport across the blood-brain barrier and distribution within the brain tissue [14], it is consistent with our previous work using PET nomenclature [13],[15]. A derivation of Eq. 1 from PET nomenclature is provided as supplementary information (Additional file 2), as is a template spreadsheet for calculation of ftb (Additional file 3).

The brain slice method

The Vu,brain values for all available tracers were determined using a high-throughput brain slice method exactly as described previously [11], employing tracer analysis by liquid chromatography tandem mass spectrometry (LC-MS/MS). The studies were approved by the Animal Ethics Committee of Gothenburg (234-2011).

Results

Table 1 presents the literature data of Kd and Bmax for each tracer and target along with the values of Vu,brain determined in rat brain slices or calculated from reported data of binding in brain homogenate (fu,brain). The dataset contained observations that span 3-4 orders of magnitude for each entity; the highest and lowest target expression level in the dataset was 1,407 and 0.2 nM for amyloid β protein aggregates and the nicotinic acetylcholine receptor respectively; the tracer affinities for their targets ranged from 0.016 to 270 nM for GR205171 and Remoxipride, respectively, and in terms of non-specific binding sertraline had the highest Vu,brain value (4,200 mL•g brain-1) and 2-FA-85380 the lowest (1.7 mL•g brain-1).

The target-bound fraction of tracer (ftb) could be derived from in vivo PET data for 33 of 35 functioning tracers but not for 11/12 non-functional tracers for which an arbitrary low value (0.09) was assigned (Table 1). The values of ftb ranged from for very low (<0.1) for most non-functioning tracers to 0.96 for [11C]Fallypride. In vitro predictions of ftb, based on the brain slice method and literature data (Eq. 3), displayed a range of values from 0.02 for [11C]Remoxipride to 0.99 for [11C]Fallypride (Table 1). In general, tracers with predicted high ftb values had higher observed PET values for ftb than did tracers with low or moderate predicted ftb values (Figure 3). A cutoff value of 0.4 for ftb was used to correctly classify 31/35 functioning tracers (89% sensitivity) and 12/12 non-functioning tracers (100% specificity).
Figure 3

Relationship between in vitro predicted and PET-derived f tb for functioning tracers ( blue ) and non-functioning tracers ( red ). The solid and dashed lines represent identity and the proposed cut-off value for ftb, respectively.

Classification accuracy was determined also for the traditional CNS PET tracer selection criteria (Figure 1) and illustrated in Figure 4. Second to the presented ftb classification, which correctly classified all of the non-functioning tracers, was the Vu,brain criterion (Vu,brain ≤20 mL•g brain-1) resulting in 10/12 correct classifications. This Vu,brain criterion, however, only classified 13/35 functional tracers correctly. With respect to functioning tracers, ftb predictions were superseded by the Bmax/Kd criterion (Bmax/Kd ≥ 10); however, Bmax/Kd classified correctly only 6/12 non-functioning tracers. When combining the classification of both functional and non-functional tracers, ftb prediction resulted in 43/47 (91%) correct classifications followed by the Bmax/Kd criterion giving 39/47 (83%) correct classifications. The MPO score, which does not rely on experimental data, made a total of 28/47 correct classifications. A poor overall rate (23/47) of correct classification was observed for the logD-based criterion, which was originally conceived with the intention to limit non-specific tissue binding while allowing a certain degree of lipophilicity to have sufficient brain exposure. To test the capability of logD to predict non-specific binding, a comparison of ACDLogD7.4 and Vu,brain was made and illustrated in Figure 5.
Figure 4

Alignment of in vitro predicted f tb ( top panel ) and common PET ligand selection critera with the present PET tracer dataset.

Figure 5

Lack of close correlation between ACDlogD7.4 and V u,brain for the functioning ( blue ) and non-functioning ( red ) PET tracers. Dashed lines represent commonly applied PET-ligand selection criteria; vertical lines border the desired range of lipophilicity, and the horizontal line indicates the maximum level of non-specific binding.

Discussion

This study presents a mechanistically integrated approach for effective identification of PET tracer candidates based on simple and well-established theory. A prediction of the target-bound fraction of tracer (ftb) was made from measurements of target affinity, density, and the non-specific binding of the tracer measured in brain slices. The results show that a cutoff value of 0.4 for ftb can be used to correctly classify 91% of tracer candidates as either being functioning or non-functioning. Hence, a predicted ftb value greater than 0.4 can be seen as strong support to proceed with the development of a PET tracer, and a low value (<0.4) indicates small chances of success.

While keeping in mind that the aim of predicting ftb is to improve decision making in the selection of PET-tracer candidates, a discussion is warranted on the agreement between predicted and observed ftb at a quantitative level. The deviation from perfect agreement, which is seen as scatter around the line of identity in Figure 3, is not marginal and represents a combined `error' from several sources. Obviously, the simple model used for ftb (Eq. 3) may not always be sufficient to describe the full complexity of non-specific and specific binding as they occur in vivo. There is also considerable measurement-related error that is invariably associated with the approach taken in this study: to combine experimental data for typically three independent measurements/reports (Bmax, Kd, and Vu,brain) and compare with a PET-derived value of ftb, also carrying a measurement error. Considering that the accuracy of experimental methods such as those relating to Bmax, Kd and Vu,brain are sometimes regarded as `within 3-fold'; it would seem that the predictions are no worse than should be expected from experimental error alone. An illuminating example is [11C]DASB for which the reported Kd values ranged between 0.2 and 3.5 nM, corresponding to predicted ftb values between 0.86 to 0.26. In this instance, the extreme value of 3.5 nM was used for Kd because it was the first encountered human value, despite the resulting in miss-classification as non-functioning. Another noteworthy example from this dataset is PK11195, which was misclassified by the model as non-functioning. Despite being a widely used marker for neuroinflammation, PK11195 binding in the brain has a relatively high non-specific component and was even designated as a non-functioning tracer by Zhang et al. in a recent publication [10]. In favor of the discriminating ability of the current model, the second generation TSPO radioligand PBR28 was ranked higher than PK11195. Nevertheless, PK11195 has some clinical utility, partly associated with its genotype aspecific binding, which should not be disregarded in this context.

It follows from the presented results that a default strategy at the outset of a tracer development campaign for a new target is to identify molecules with a combination of high affinity for the target and low non-specific binding, i.e. minimal values for the Kd × Vu,brain product. Depending on the density of the particular target (Bmax), different threshold values exist for Kd × Vu,brain to give rise to sufficiently high value of ftb and hence a functional PET tracer. This integrative approach contrasts with the traditional process for PET tracer identification, which has been based on benchmarking against a set of discrete criteria. Integration is evidently essential as no single criterion displays prediction sensitivity and specificity that are comparable to that of the ftb model. Furthermore, using all five analyzed criteria in Figure 4 as strict filters would result in the erroneous elimination of 86% of all functioning ligands; in fact, just two criteria (Vu,brain < 20 mL/g brain and clogD of 1-3) results in a 74% erroneous elimination. In the present dataset there is poor correlation between lipophilicity (ACDlogD7.4) and Vu,brain (Figure 5), suggesting that lipophilicity should not be used to predict non-specific binding. Recently, a CNS PET MPO score was developed from a PET ligand dataset [10]. This score is a composite of various calculated molecular descriptors and therefore represents an interesting integration of molecular properties that could be used alongside experimentally predicted ftb or by itself to prioritize between new molecular structures before chemical synthesis is made.

A prerequisite for making in vitro predictions of ftb is access to reliable assays for experimental determination of Kd, Vu,brain, and Bmax. At the stage of PET tracer development, there is almost always an assay available for the target: if not a binding assay yielding Kd then at least a functional assay of potency (EC50 or IC50). Vu,brain is best measured in vitro using the high-throughput brain slice methodology [11]. However, for the present integrated approach it may be sufficient to use the more readily available equilibrium dialysis brain homogenate binding assay and apply correction factors on the basis of drug pKa[12]. Determination of Bmax can pose a significant challenge since it generally requires a suitable in vitro radioligand. However, regardless of the Bmax value, the initial objective of tracer optimization can be to minimize the Kd × Vu,brain product, even though the target level is not defined. If the target Bmax is determined or known beforehand, the ftb prediction model can be used not only to rank-order tracer candidates but also to assess the likelihood of being successful in identifying a tracer for a particular target. Furthermore, it is our experience that it is useful to determine Bmax both in the preclinical species and human to facilitate the translation of ftb and thereby reduce the risk of attrition.

The presented approach does not specifically address the effects of drug efflux at the blood-brain barrier or the impact of tracer metabolites in the brain, yet it predicts the present dataset with good precision and accuracy. It is possible that there is a selection bias in the dataset owing to the fact that a majority of tracers are either CNS drugs, established functioning tracers, or both. Therefore, ftb predictions should be supplemented with predictions of CNS exposure using in vivo, in vitro, or in silico techniques. Prediction of the level of tracer metabolites in the brain is not straightforward; however, it appears to not deteriorate the predictive value of the model, which is consistent with metabolites generally having more hydrogen bond acceptors and therefore increased probability of being effluxed at the blood-brain barrier. In summary, we recognize that a poor ratio of specific to non-specific binding is one of the primary reasons for attrition in PET-tracer development and we expect this to be managed with ftb predictions.

Conclusions

A mechanistically integrated method for the identification of CNS tracer candidates was developed in which the non-specific binding, tracer affinity, and the target protein expression in the brain were taken into account. The method is rapid and accurate and is expected to facilitate the development of novel PET tracers for the molecular imaging community.

Authors' contributions

Contributions to the conception of the study and its design were made by MF, MW, MA, LF, and MS. MS-S carried out brain slice experiments. MF and MS conducted the literature review and drafted the manuscript together with LF. All authors read and approved the final manuscript.

Additional files

Abbreviations

Bmax

target density

BPND

non-displaceable binding potential

ftb

target-bound fraction of tracer

Kd

ligand affinity to target protein

MPO: 

multiparameter optimization

PET: 

positron emission tomography

Declarations

Acknowledgements

The authors thank Ingela Ahlstedt, Anudharan Balendran, Gunilla Jerndal, Marie Johansson, and Petter Svanberg for helpful discussions and participation in generation of brain slice data.

Authors’ Affiliations

(1)
Respiratory Inflammation and Autoimmunity Innovative Medicines, AstraZeneca R&D
(2)
Translational PKPD, Department of Pharmaceutical Biosciences, Uppsala University
(3)
Cardiovascular and Metabolic Diseases Innovative Medicines, AstraZeneca R&D
(4)
CNS & Pain Innovative Medicines, AstraZeneca R&D
(5)
AstraZeneca Translational Science Centre, Department of Clinical Neuroscience, Karolinska Institutet

References

  1. Pike VW: PET radiotracers: crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol Sci 2009, 30: 431-440. 10.1016/j.tips.2009.05.005PubMed CentralView ArticlePubMedGoogle Scholar
  2. Halldin C, Gulyas B, Langer O, Farde L: Brain radioligands-state of the art and new trends. Q J Nucl Med 2001, 45: 139-152.PubMedGoogle Scholar
  3. Cunningham VJ, Parker CA, Rabiner EA, Gee AD, Gunn RN: PET studies in drug development: methodological considerations. Drug Discov Today 2005, 2: 311-315. 10.1016/j.ddtec.2005.11.003View ArticleGoogle Scholar
  4. Waterhouse RN: Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol 2003, 5: 376-389. 10.1016/j.mibio.2003.09.014View ArticlePubMedGoogle Scholar
  5. Patel S, Gibson R: In vivo site-directed radiotracers: a mini-review. Nucl Med Biol 2008, 35: 805-815. 10.1016/j.nucmedbio.2008.10.002View ArticlePubMedGoogle Scholar
  6. Rosso L, Gee AD, Gould IR: Ab initio computational study of positron emission tomography ligands interacting with lipid molecule for the prediction of nonspecific binding. J Comput Chem 2008, 29: 2397-2405. 10.1002/jcc.20972View ArticlePubMedGoogle Scholar
  7. Jiang Z, Reilly J, Everatt B, Briard E: A rapid vesicle electrokinetic chromatography method for the in vitro prediction of non-specific binding for potential PET ligands. J Pharm Biomed Anal 2011, 54: 722-729. 10.1016/j.jpba.2010.11.004View ArticlePubMedGoogle Scholar
  8. Guo Q, Brady M, Gunn RN: A biomathematical modeling approach to central nervous system radioligand discovery and development. J Nucl Med 2009, 50: 1715-1723. 10.2967/jnumed.109.063800View ArticlePubMedGoogle Scholar
  9. Guo Q, Owen DR, Rabiner EA, Turkheimer FE, Gunn RN: Identifying improved TSPO PET imaging probes through biomathematics: the impact of multiple TSPO binding sites in vivo. Neuroimage 2012, 60: 902-910. 10.1016/j.neuroimage.2011.12.078PubMed CentralView ArticlePubMedGoogle Scholar
  10. Zhang L, Villalobos A, Beck EM, Bocan T, Chappie TA, Chen L, Grimwood S, Heck SD, Helal CJ, Hou X, Humphrey JM, Lu J, Skaddan MB, McCarthy TJ, Verhoest PR, Wager TT, Zasadny K: Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligand. J Med Chem 2013, 56: 4568-4579. 10.1021/jm400312yView ArticlePubMedGoogle Scholar
  11. Friden M, Ducrozet F, Antonsson M, Middleton B, Bredberg U, Hammarlund-Udenaes M: Development of a high-throughput brain slice method for studying drug distribution in the CNS. Drug Metab Dispos 2009, 37: 1226. 10.1124/dmd.108.026377View ArticlePubMedGoogle Scholar
  12. Friden M, Bergstrom F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M, Bredberg U: Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos 2011, 39: 353-362. 10.1124/dmd.110.035998View ArticlePubMedGoogle Scholar
  13. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE: Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metable 2007, 27: 1533-1539. 10.1038/sj.jcbfm.9600493View ArticleGoogle Scholar
  14. Hammarlund-Udenaes M, Friden M, Syvanen S, Gupta A: On the rate and extent of drug delivery to the brain. Pharm Res 2008, 25: 1737-1750. 10.1007/s11095-007-9502-2PubMed CentralView ArticlePubMedGoogle Scholar
  15. Farde L, Eriksson L, Blomquist G, Halldin C: Kinetic analysis of central [llC]Raclopride binding to D2-dopamine receptors studied by PET-a comparison to the equilibrium analysis. J Cereb Blood Flow Metable 1989, 9: 696-708. 10.1038/jcbfm.1989.98View ArticleGoogle Scholar

Copyright

© Friden et al.; licensee Springer. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.